Digitalising Health Data
Greater digitalisation promises improved efficiency, but health data are very sensitive personal data and the population’s mistrust of digitalisation needs to be taken seriously. Our survey explores what the Swiss think and their preferences regarding sensitive personal data collection and sharing.
The business case for Patient Companion Solutions
Patient companion solutions benefit various healthcare stakeholders, including providers, payers, and pharmaceutical companies. The global market for disease management apps was worth USD 8.7 billion in 2022 and is projected to grow at a rate of 12.3% annually from 2023 to 2030.
Seize the digital momentum
Measuring the return from pharmaceutical innovation 2022
The projected return on investment of the global pharmaceutical industry was down significantly from last year; forecast peak sales per asset declined by a quarter. The development process for new drugs must therefore be transformed and could be made much more efficient with digital technologies.
Investment in eye health to prevent sight loss
Investment in eye health to prevent sight loss – presents an in-depth comparison of publicly available data to understand the relationship between investment in eye health and eye outcomes across eight high-income and two low-medium-income countries.
Commercial Operations in Life Sciences
Driving simplification and efficiency across Commercial Operations
Digital transformation of commercial operations has transitioned from a “nice-to-have” enabler to a “must-have” capability, making it critical for Life Science companies to evaluate how digital tools will deliver customer centricity and service innovation across the commercial operations value chain
Segmentation and growth factors of the global neuroscience market
Sizing the brain
The report breaks down the Global Neuroscience Market (GNM) across segments and geographies. It provides a comprehensive analysis of available diagnostic and treatment options – as a proxy for market size – to estimate the revenue-based valuation of the GNM until 2026.
Advanced digital health care providers segmentation
Elevating customer understanding leveraging AI
Our advanced segmentation approach enables to define data-driven HCP segments by leveraging AI and machine learning algorithms. We display a detailed use case that describes how we have helped biopharma companies leverage data and AI to build differentiated and actionable HCP segments.
How can virtual health help expand capacity in the wake of an anticipated COVID-19 surge?
When faced with a health crisis like Covid-19, social distancing can take some of the strain off healthcare providers at the front lines. But when that’s not enough, innovations like virtual healthcare can help increase capacity, reduce the rate of infection, and treat non-urgent cases.
Forging the links across the value chain
The biopharmaceutical sector is facing digital disruption from multiple sources, the chief among them being artificial intelligence (AI) and cloud. Deloitte predicts that in 2019/2020, all industries will accelerate their use of cloud-based AI software and services, including biopharma companies.
Intelligent drug launch and commercial
Optimising value through AI
This is the fifth report in our Intelligent biopharma series, which explores the current and future potential of artificial intelligence (AI) across the biopharma value chain. This report focuses on how companies can use AI to improve drug launches and their commercial models.
COVID-19: Shaping the future regulation of emergency medical equipment supply
The COVID-19 pandemic has disrupted everyone’s daily lives and touched every industry across the world. While many countries had influenza and other pandemic preparedness plans in place prior to COVID-19, no one was fully prepared for the speed and indiscriminate spread of the disease.
Predicting the future of healthcare and life sciences in 2025
The future unmasked
What does the future hold for the life sciences and healthcare industry? Our latest predictions report looks ahead to the year 2025 to help you see what’s coming and to keep your organisation moving forward.
Securing trust in the global COVID-19 supply chain
From development and delivery to acceptance and administration
COVID-19 vaccines and therapeutics, and the associated medical devices and consumables, present an urgent need for a protected supply chain and a system of traceability built around globally identified products.
Accelerating the Future of Health
COVID-19 responses from the health ecosystem
Responding to COVID-19 is an enormous challenge for companies of all sizes and in all sectors, not least life sciences. The pandemic is affecting the pharmaceutical ecosystem and highlighting the importance of health technology economically, politically, and socially.
ConvergeHEALTH Connect for Crisis Response
In response to the spread of coronavirus around the world, Deloitte has developed an accelerator designed to enable health care organisations to digitally triage, monitor and remotely manage treatment of coronavirus patients and quarantined persons.
Pioneering MedTech Transformation
Deloitte helps MedTech companies of all sizes innovate their business models and scale. This enables companies to meet changing demands. and transition towards a redefined ecosystem prioritizing wellness and prevention.
Biotech-in-a-box™️ aims to provide a ‘one-stop shop’ for small-to-medium size life sciences companies to de-risk the scaling up of their business by leveraging Deloitte’s portfolio of capabilities.
The Future of Manufacturing Operations
The Future of Manufacturing Operations is Deloitte’s unique approach to help you reshape your business through digital transformation.
Deloitte has extensive relationships with pharmaceutical companies across the whole spectrum of size and geography.
Switzerland is one of the top biotechnology locations in Europe. Biotechnology remains a firm agenda item in the approach to drug development and Switzerland is leading the way.